Anakinra—an interleukin-1 receptor antagonist for COVID-19
Background: Coronavirus disease (COVID-19) caused by SARS-CoV-2 virus caused a
global pandemic in 2019. There are limited pharmacologic options available. The Food and …
global pandemic in 2019. There are limited pharmacologic options available. The Food and …
Current evidence on the use of anakinra in COVID-19
Despite the progressing knowledge in COVID-19 management, remdesivir is the only agent
that got approval to inhibit viral replication. However, there are limited data about effective …
that got approval to inhibit viral replication. However, there are limited data about effective …
[HTML][HTML] Use of anakinra in severe COVID-19: a case report
Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant
inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a …
inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a …
[HTML][HTML] The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases of COVID-19: a systematic review and meta-analysis
MKR Somagutta, MKL Pormento, P Hamid… - Infection & …, 2021 - ncbi.nlm.nih.gov
This study aims to assess anakinra's safety and efficacy for treating severe coronavirus
disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 …
disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 …
A meta analysis on the utility of Anakinra in severe COVID-19 disease
AARM Hussein, R Sayad, A Abdelshafi, IA Hammam… - Cytokine, 2023 - Elsevier
Background and objective The most important presentation of COVID-19 is hyper
inflammatory condition and cytokine storm that occurs due to excessive increase of the …
inflammatory condition and cytokine storm that occurs due to excessive increase of the …
[HTML][HTML] Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
M Franzetti, U Pozzetti, M Carugati, A Pandolfo… - International Journal of …, 2020 - Elsevier
We report the first successful treatment with the IL-1 receptor antagonist anakinra, in
association with the most promising and available antiviral therapy, of a severe case of …
association with the most promising and available antiviral therapy, of a severe case of …
[HTML][HTML] Anakinra in COVID-19: A step closer to the cure
Acute respiratory distress syndrome and cytokine release syndrome are the major
complications of coronavirus disease 2019 (COVID-19) associated with increased mortality …
complications of coronavirus disease 2019 (COVID-19) associated with increased mortality …
[HTML][HTML] IL-1 receptor antagonist anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study
M Franzetti, A Forastieri, N Borsa… - The Journal of …, 2021 - journals.aai.org
The IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute
respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …
respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID …
A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19
Introduction Hyperinflammatory state has a role in the pathogenesis of COVID‐19. Anakinra
could reduce inflammation and help to combat the condition. In this study, we aimed to …
could reduce inflammation and help to combat the condition. In this study, we aimed to …
Evaluation of anakinra in the management of patients with COVID-19 infection: A randomized clinical trial
EZI Elmekaty, A Maklad, R Abouelhassan… - Frontiers in …, 2023 - frontiersin.org
Background The global COVID-19 pandemic led to substantial clinical and economic
outcomes with catastrophic consequences. While the majority of cases has mild to moderate …
outcomes with catastrophic consequences. While the majority of cases has mild to moderate …